Our data suggest that the combination of the high-affinity CD16+ NK line, haNK, and a humanized anti-CD123 mAb, CSL362, suggests a novel approach to investigate in the treatment of patients with relapsed/resistant CD123+ HL. This evidence concerns the gene IL3RA and Hodgkins lymphoma.